GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

While both medications showed a significant weight loss benefit, after 72 weeks on treatment, people treated with Zepbound lost 20% of their body weight, compared to people on Wegovy who lost just ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.

Share on Pinterest Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Shelby Knowles/Bloomberg via Getty Images Zepbound led to more long ...

The results from the trial show Zepbound results in 47 percent more weight loss among adult users compared to those taking Novo Nordisk’s Wegovy. Adults using Zepbound weekly lost about 20 ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

According to Eli Lilly, the study showed that both medications offer significant weight loss benefits, but people treated with Zepbound lost more weight than those on Wegovy after 72 weeks of ...

That translates to an average weight loss of about 50 pounds for those taking Zepbound, compared with an average weight loss of 33 pounds for those taking Wegovy. People taking Zepbound were also ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...